Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 44

1.

Activation of latent transforming growth factor-β1, a conserved function for pregnancy-specific beta 1-glycoproteins.

Warren J, Im M, Ballesteros A, Ha C, Moore T, Lambert F, Lucas S, Hinz B, Dveksler G.

Mol Hum Reprod. 2018 Dec 1;24(12):602-612. doi: 10.1093/molehr/gay044.

2.

Structural basis of latent TGF-β1 presentation and activation by GARP on human regulatory T cells.

Liénart S, Merceron R, Vanderaa C, Lambert F, Colau D, Stockis J, van der Woning B, De Haard H, Saunders M, Coulie PG, Savvides SN, Lucas S.

Science. 2018 Nov 23;362(6417):952-956. doi: 10.1126/science.aau2909. Epub 2018 Oct 25.

PMID:
30361387
3.

Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma.

Lopes A, Vanvarenberg K, Kos Š, Lucas S, Colau D, Van den Eynde B, Préat V, Vandermeulen G.

Sci Rep. 2018 Oct 24;8(1):15732. doi: 10.1038/s41598-018-33933-7.

4.

Deletion of GARP on mouse regulatory T cells is not sufficient to inhibit the growth of transplanted tumors.

Vermeersch E, Liénart S, Collignon A, Lucas S, Gallimore A, Gysemans C, Unutmaz D, Vanhoorelbeke K, De Meyer SF, Maes W, Deckmyn H.

Cell Immunol. 2018 Oct;332:129-133. doi: 10.1016/j.cellimm.2018.07.011. Epub 2018 Jul 30.

PMID:
30093071
5.

Regulatory T cells control toxicity in a humanized model of IL-2 therapy.

Li Y, Strick-Marchand H, Lim AI, Ren J, Masse-Ranson G, Dan Li, Jouvion G, Rogge L, Lucas S, Bin Li, Di Santo JP.

Nat Commun. 2017 Nov 24;8(1):1762. doi: 10.1038/s41467-017-01570-9.

6.

Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8.

Stockis J, Liénart S, Colau D, Collignon A, Nishimura SL, Sheppard D, Coulie PG, Lucas S.

Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):E10161-E10168. doi: 10.1073/pnas.1710680114. Epub 2017 Nov 6.

7.

Role of GARP in the activation of latent TGF-β1.

Stockis J, Dedobbeleer O, Lucas S.

Mol Biosyst. 2017 Sep 26;13(10):1925-1935. doi: 10.1039/c7mb00251c. Review.

PMID:
28795730
8.

Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects.

Ehx G, Fransolet G, de Leval L, D'Hondt S, Lucas S, Hannon M, Delens L, Dubois S, Drion P, Beguin Y, Humblet-Baron S, Baron F.

Oncoimmunology. 2017 Apr 12;6(5):e1314425. doi: 10.1080/2162402X.2017.1314425. eCollection 2017.

9.

Cutting Edge: Active TGF-β1 Released from GARP/TGF-β1 Complexes on the Surface of Stimulated Human B Lymphocytes Increases Class-Switch Recombination and Production of IgA.

Dedobbeleer O, Stockis J, van der Woning B, Coulie PG, Lucas S.

J Immunol. 2017 Jul 15;199(2):391-396. doi: 10.4049/jimmunol.1601882. Epub 2017 Jun 12.

10.

Targeting immunosuppression by Tregs with monoclonal antibodies against GARP.

Liénart S, Stockis J, Dedobbeleer O, Lucas S.

Oncoimmunology. 2016 Feb 23;5(3):e1074379. eCollection 2016 Mar.

11.

[Immunosuppression by Treg can be decreased with anti-GARP antibodies].

Lucas S.

Med Sci (Paris). 2015 Oct;31(10):832-4. doi: 10.1051/medsci/20153110007. Epub 2015 Oct 19. French. No abstract available.

12.

Lysosomal-associated Transmembrane Protein 4B (LAPTM4B) Decreases Transforming Growth Factor β1 (TGF-β1) Production in Human Regulatory T Cells.

Huygens C, Liénart S, Dedobbeleer O, Stockis J, Gauthy E, Coulie PG, Lucas S.

J Biol Chem. 2015 Aug 14;290(33):20105-16. doi: 10.1074/jbc.M115.655340. Epub 2015 Jun 30.

13.

Circulating Follicular Regulatory T Cells Are Defective in Multiple Sclerosis.

Dhaeze T, Peelen E, Hombrouck A, Peeters L, Van Wijmeersch B, Lemkens N, Lemkens P, Somers V, Lucas S, Broux B, Stinissen P, Hellings N.

J Immunol. 2015 Aug 1;195(3):832-40. doi: 10.4049/jimmunol.1500759. Epub 2015 Jun 12.

14.

Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo.

Cuende J, Liénart S, Dedobbeleer O, van der Woning B, De Boeck G, Stockis J, Huygens C, Colau D, Somja J, Delvenne P, Hannon M, Baron F, Dumoutier L, Renauld JC, De Haard H, Saunders M, Coulie PG, Lucas S.

Sci Transl Med. 2015 Apr 22;7(284):284ra56. doi: 10.1126/scitranslmed.aaa1983.

15.

Leukemia inhibitory factor tips the immune balance towards regulatory T cells in multiple sclerosis.

Janssens K, Van den Haute C, Baekelandt V, Lucas S, van Horssen J, Somers V, Van Wijmeersch B, Stinissen P, Hendriks JJ, Slaets H, Hellings N.

Brain Behav Immun. 2015 Mar;45:180-8. doi: 10.1016/j.bbi.2014.11.010. Epub 2014 Dec 13.

PMID:
25514345
16.

Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism.

Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, Chen W, Scher JU, Mo R, Depoil D, Rao N, Liu B, Wei J, Lucas S, Koslow M, Roche M, Schueller O, Weiss S, Poyurovsky MV, Tonra J, Hippen KL, Dustin ML, Blazar BR, Liu CJ, Waksal SD.

Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9. doi: 10.1073/pnas.1414189111. Epub 2014 Nov 10.

17.

GARP is regulated by miRNAs and controls latent TGF-β1 production by human regulatory T cells.

Gauthy E, Cuende J, Stockis J, Huygens C, Lethé B, Collet JF, Bommer G, Coulie PG, Lucas S.

PLoS One. 2013 Sep 30;8(9):e76186. doi: 10.1371/journal.pone.0076186. eCollection 2013.

18.

Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease.

Hannon M, Lechanteur C, Lucas S, Somja J, Seidel L, Belle L, Bruck F, Baudoux E, Giet O, Chantillon AM, Delvenne P, Drion P, Beguin Y, Humblet-Baron S, Baron F.

Transfusion. 2014 Feb;54(2):353-63. doi: 10.1111/trf.12279. Epub 2013 Jun 17.

19.

Platelet-derived growth factor-producing CD4+ Foxp3+ regulatory T lymphocytes promote lung fibrosis.

Lo Re S, Lecocq M, Uwambayinema F, Yakoub Y, Delos M, Demoulin JB, Lucas S, Sparwasser T, Renauld JC, Lison D, Huaux F.

Am J Respir Crit Care Med. 2011 Dec 1;184(11):1270-81. doi: 10.1164/rccm.201103-0516OC. Epub 2011 Aug 25.

PMID:
21868503
20.

Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.

Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG.

Clin Cancer Res. 2011 Sep 1;17(17):5725-35. doi: 10.1158/1078-0432.CCR-11-1261. Epub 2011 Jul 19.

Supplemental Content

Loading ...
Support Center